Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis

Chin Med J (Engl). 2022 Sep 20;135(18):2248-2250. doi: 10.1097/CM9.0000000000002143.

Authors

Si Zhang¹, Lin Cai¹, Heng Zhang¹, Zheng Zhao^{1

2}, Xiaoyang Liu¹, Yan Zhao¹, Jianzhong Zhang¹

Affiliations

¹ Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
² Department of Dermatology, Peking University International Hospital, Beijing 102206, China.

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Adalimumab
secukinumab
Antibodies, Monoclonal, Humanized